# DYM

## Overview
The DYM gene encodes the dymeclin protein, a peripheral non-anchored Golgi protein involved in the organization of the Golgi apparatus and protein secretion pathways essential for bone development. Dymeclin is characterized by its six transmembrane regions and is expressed in various tissues, including the brain, chondrocytes, osteoblasts, and skin fibroblasts (Gaboon2020A; Denais2011Dymeclin; Bakar2023A). It plays a crucial role in intracellular vesicle trafficking, particularly within the Golgi complex, and interacts with several proteins involved in vesicular traffic, such as p115/VDP, COPB, and VPS35 (Osipovich2008Dyggve–Melchior–Clausen). Mutations in the DYM gene are linked to skeletal disorders such as Dyggve-Melchior-Clausen syndrome and Smith-McCort dysplasia, highlighting its significance in bone development and Golgi homeostasis (Dimitrov2008The; Dupuis2015Dymeclin).

## Structure
The DYM gene encodes the dymeclin protein, which is composed of 669 amino acids and includes six transmembrane regions with the N-terminus located inside the cytoplasm (Denais2011Dymeclin; Bakar2023A). The secondary structure of dymeclin includes an α helix, and its tertiary structure was predicted using the I-Tasser server, resulting in a C-score of 0.8 and a Tm-score of 0.7, indicating a reliable model (Bakar2023A). The Ramachandran plot analysis showed that 98% of residues were in favored conformations, supporting the model's reliability (Bakar2023A). The protein's domain architecture comprises extracellular, intracellular, and transmembrane domains (Bakar2023A). 

Dymeclin is involved in Golgi organization and protein secretion pathways, which are critical for bone development (Denais2011Dymeclin). It is a peripheral non-anchored Golgi protein capable of shuttling between cellular compartments (Denais2011Dymeclin). The protein is expressed in the human brain, chondrocytes, osteoblasts, and skin fibroblasts (Gaboon2020A). Specific post-translational modifications and splice variant isoforms have not been detailed in the available context.

## Function
The DYM gene encodes the dymeclin protein, which is integral to the organization of the Golgi apparatus and the extracellular matrix, playing a crucial role in protein secretion pathways essential for bone development (Denais2011Dymeclin). Dymeclin is highly concentrated in the Golgi apparatus but is also present in the cytosol, indicating its role as a peripheral non-anchored Golgi protein capable of shuttling between cellular compartments (Denais2011Dymeclin). It is involved in intracellular vesicle trafficking, particularly in the Golgi complex, which is crucial for processing, sorting, and transporting secreted proteins in mammalian cells (Osipovich2008Dyggve–Melchior–Clausen).

Dymeclin interacts with various proteins involved in vesicular traffic, such as p115/VDP, COPB, and VPS35, which are essential for ER-to-Golgi and Golgi-to-ER traffic, endosome-Golgi sorting, and Golgi assembly (Osipovich2008Dyggve–Melchior–Clausen). The protein is predicted to have multiple membrane-spanning domains and trafficking motifs, suggesting it may act as a membrane-spanning adaptor influencing vesicle budding, movement, sorting, and fusion (Osipovich2008Dyggve–Melchior–Clausen). Dymeclin's role in maintaining Golgi structure is highlighted by its involvement in Golgi ribbon formation and tethering, which are critical for normal cellular function and bone development (Denais2011Dymeclin).

## Clinical Significance
Mutations in the DYM gene, which encodes the protein Dymeclin, are associated with two autosomal recessive skeletal disorders: Dyggve-Melchior-Clausen (DMC) syndrome and Smith-McCort (SMC) dysplasia. DMC syndrome is characterized by severe mental retardation, skeletal dysplasia, and specific facial dysmorphisms. It results from loss-of-function mutations in the DYM gene, leading to mis-localization and degradation of Dymeclin, which contributes to the cognitive and skeletal abnormalities observed in affected individuals (Dimitrov2008The; Dupuis2015Dymeclin). 

In contrast, SMC dysplasia is a clinical variant of DMC that shares similar skeletal features but lacks the neurological impairments. This condition is caused by missense mutations in the DYM gene that do not lead to Dymeclin degradation, such as the E87K mutation, which may explain the absence of mental retardation in SMC patients (Dimitrov2008The; Dupuis2015Dymeclin). Both conditions are linked to defects in endochondral bone formation, affecting chondrocyte proliferation and differentiation, which are critical for normal bone growth and development (Osipovich2008Dyggve–Melchior–Clausen). Understanding these mutations provides insights into the role of Dymeclin in Golgi homeostasis and vesicular trafficking (Dupuis2015Dymeclin).

## Interactions
Dymeclin, encoded by the DYM gene, is involved in various protein interactions critical for intracellular vesicle traffic and Golgi organization. It interacts with several proteins, including Golgi and ER-resident proteins, vesicular transport proteins, and nuclear transport proteins. Notable interactions include those with coatomer protein complex subunits, clathrin-adaptor protein 1 complex subunits, Golgi vesicle docking protein p115, SNARE protein YKT6, Golgi tethering protein giantin, and retromer complex VPS35 (Osipovich2008Dyggve–Melchior–Clausen). Dymeclin also coprecipitates with exportin 1, coatomer protein subunit β (COPB), adaptor protein 1 subunit 1 (AP1G1), vesicle docking protein p115 (VDP), vacuolar sorting protein (VPS35), leucine-rich PPR-motif containing protein (LRPPRC), DNM1L, and β tubulin (TUBB) (Osipovich2008Dyggve–Melchior–Clausen).

In addition, Dymeclin interacts with PPIB and GOLM1, as identified through yeast two-hybrid screens and GST pull-down assays. These interactions were confirmed in mammalian cells, where PPIB co-localizes with Dymeclin in a perinuclear distribution, likely within Golgi and/or ER structures (Denais2011Dymeclin). These interactions suggest Dymeclin's involvement in ER-Golgi secretion and export pathways, which are essential for bone development and maintaining Golgi structure (Denais2011Dymeclin).


## References


[1. (Bakar2023A) Abu Bakar, Sulaiman Shams, Nousheen Bibi, Asmat Ullah, Wasim Ahmad, Musharraf Jelani, Osama Yousef Muthaffar, Angham Abdulrhman Abdulkareem, Turki S. Abujamel, Absarul Haque, Muhammad Imran Naseer, and Bushra Khan. A novel homozygous nonsense variant in the dym underlies dyggve-melchior-clausen syndrome in large consanguineous family. Genes, 14(2):510, February 2023. URL: http://dx.doi.org/10.3390/genes14020510, doi:10.3390/genes14020510. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/genes14020510)

[2. (Dimitrov2008The) Ariane Dimitrov, Vincent Paupe, Charles Gueudry, Jean-Baptiste Sibarita, Graça Raposo, Ole Vielemeyer, Thierry Gilbert, Zsolt Csaba, Tania Attie-Bitach, Valérie Cormier-Daire, Pierre Gressens, Pierre Rustin, Franck Perez, and Vincent El Ghouzzi. The gene responsible for dyggve-melchior-clausen syndrome encodes a novel peripheral membrane protein dynamically associated with the golgi apparatus. Human Molecular Genetics, 18(3):440–453, November 2008. URL: http://dx.doi.org/10.1093/hmg/ddn371, doi:10.1093/hmg/ddn371. This article has 29 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddn371)

[3. (Gaboon2020A) Nagwa E. A. Gaboon, Asia Parveen, Khaled A. Ahmad, Taghreed Shuaib, Jumana Y. Al-Aama, Lereen Abdelwehab, Amina Arif, and Naveed Wasif. A novel homozygous frameshift variant in dym causing dyggve-melchior-clausen syndrome in pakistani patients. Frontiers in Pediatrics, July 2020. URL: http://dx.doi.org/10.3389/fped.2020.00383, doi:10.3389/fped.2020.00383. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fped.2020.00383)

[4. (Denais2011Dymeclin) Celine Denais, Carolyn L. Dent, Laura Southgate, Jacqueline Hoyle, Dimitra Dafou, Richard C. Trembath, and Rajiv D. Machado. Dymeclin, the gene underlying dyggve-melchior-clausen syndrome, encodes a protein integral to extracellular matrix and golgi organization and is associated with protein secretion pathways critical in bone development. Human Mutation, 32(2):231–239, January 2011. URL: http://dx.doi.org/10.1002/humu.21413, doi:10.1002/humu.21413. This article has 27 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.21413)

[5. (Dupuis2015Dymeclin) Nina Dupuis, Assia Fafouri, Aurélien Bayot, Manoj Kumar, Tifenn Lecharpentier, Gareth Ball, David Edwards, Véronique Bernard, Pascal Dournaud, Séverine Drunat, Marie Vermelle-Andrzejewski, Catheline Vilain, Marc Abramowicz, Julie Désir, Jacky Bonaventure, Nelly Gareil, Gaelle Boncompain, Zsolt Csaba, Franck Perez, Sandrine Passemard, Pierre Gressens, and Vincent El Ghouzzi. Dymeclin deficiency causes postnatal microcephaly, hypomyelination and reticulum-to-golgi trafficking defects in mice and humans. Human Molecular Genetics, 24(10):2771–2783, February 2015. URL: http://dx.doi.org/10.1093/hmg/ddv038, doi:10.1093/hmg/ddv038. This article has 23 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddv038)

[6. (Osipovich2008Dyggve–Melchior–Clausen) Anna B. Osipovich, Jennifer L. Jennings, Qing Lin, Andrew J. Link, and H. Earl Ruley. Dyggve–melchior–clausen syndrome: chondrodysplasia resulting from defects in intracellular vesicle traffic. Proceedings of the National Academy of Sciences, 105(42):16171–16176, October 2008. URL: http://dx.doi.org/10.1073/pnas.0804259105, doi:10.1073/pnas.0804259105. This article has 33 citations.](https://doi.org/10.1073/pnas.0804259105)